金吾财讯 | 再鼎医药(ZLAB)盘前涨超8%,截至发稿,报39.39美元。消息面上,再鼎医药发布截至2024年12月31日止年度年度业绩,总收入3.99亿美元,同比增加49.59%;研发开支2.35亿美元。营收增长主要得益于产品收入的增加。年报显示,报告期内,公司产品收入净额增加1.31亿美元,同比增加49%至3.98亿美元,主要受卫伟迦(商品名)自2023年9月上市及于2024年1月被纳入国家...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.